QTORIN rapamycin gel
Other rare keratin disorders
Preclinical / ExplorationActive
Key Facts
Indication
Other rare keratin disorders
Phase
Preclinical / Exploration
Status
Active
Company
About Palvella Therapeutics
Palvella Therapeutics is a publicly traded biotech company advancing QTORIN rapamycin gel, its lead product candidate, for the debilitating genetic skin disease pachyonychia congenita (PC), with positive Phase 3 data reported. The company's strategy is centered on addressing niche, orphan dermatological indications where it can establish rapid and definitive development paths. With a valuation of $1.62B, Palvella is positioned to potentially bring the first approved therapy to the PC market. Its success hinges on the regulatory approval and subsequent commercialization of its lead asset.
View full company profile